Enrollment Resumes in GALACTIC-1 Trial of Inhaled Therapy GB0139

Enrollment Resumes in GALACTIC-1 Trial of Inhaled Therapy GB0139

299359

Enrollment Resumes in GALACTIC-1 Trial of Inhaled Therapy GB0139

Enrollment has resumed, under a revised trial protocol, in the Phase 2b study GALACTIC-1, which is evaluating Galecto’s investigational inhaled therapy GB0139 in adults with idiopathic pulmonary fibrosis (IPF). Galecto in March had been advised to stop recruiting and treating certain trial participants after disparities were found in a safety review. All treatments with the higher 10 mg dose of GB0139 were halted, as were those with the lower 3 mg dose given in combination…

You must be logged in to read/download the full post.